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Abstract
The selective α1-adrenergic receptor antagonist doxazosin is used for the  
treatment of hypertension. More recently, an experimental report demonstrated 
that this compound exhibits antiproliferative activity in breast cancer cell lines 
with similar inhibitory activity to gefitinib, a selective inhibitor of EGFR in the 
active state (EGFRAC). This experimental study provided evidence that doxazosin 
can be employed as an anticancer compound, however, the structural basis for its 
inhibitory properties is poorly understood at the atomic level. To gain insight about 
this molecule, molecular dynamics (MD) simulation with the molecular mechanics 
generalized Born surface area (MMGBSA) approach was employed to explore the 
structural and energetic features that guide the inhibitory properties of doxazosin 
and gefitinib in overexpressing EGFR/HER2 cell lines. Our result suggest that 
doxazosin exerts its inhibitory properties in breast cancer cell lines by targeting 
EGFR/HER2 but mainly HER2 in the inactive state (HER2IN), whereas gefitinib by 
targeting mainly EGFRAC, in line with previous literature. Decomposition of the 
binding affinity into individual contributions of HER2IN-doxazosin and EGFRAC-gefitinib 
systems detected hot spot residues but also showed polar interactions of  
Met801/Met793 with the quinazoline ring of both compounds. Principal compo-
nent (PC) analysis revealed that the molecular recognition of the HER2IN-doxazosin 
system was linked to conformational changes but EGFRAC-gefitinib was not.
Keywords: HER2, EGFR, doxazosin, docking, MD simulations
1. Introduction
Human epidermal growth factor receptor 1 (EGFR) and 2 (HER2) form part of a 
family of human epidermal grown factor receptors (EGFRs), and whose phosphory-
lation impacts cell proliferation, differentiation, and migration [1]. The cytoplasmic 
tyrosine kinase domain (TKD) is considered one of the most studied receptors for 
developing new anticancer drugs [2]. Activation of EGFR starts the molecular rec-
ognition of endogenous growth factors at the extracellular domain that, at the time, 
promotes the formation of homo- and heterodimers among the different members 
of EGFR, with HER2 the preferred member of EGFRs to form heterodimers [3–5]. 
The transition from a monomeric to dimeric state in EGFR is coupled to a confor-
mational change in the TKD from an inactive to active state [6–8], whereas that for 
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HER2 transitions from inactive, intermediate, and inactive states [9–11]. Generally, 
the signaling activity regulated by EGFR/HER2 is under control, however, mutations 
in TKD give place to constitutive activation of these receptors, which results in the 
development of different types of cancer, such as lung [12] and breast cancer [13]. 
In addition, overexpression of EGFR/HER2 also happens with radiotherapy and 
chemotherapy resistance [14–16].
Based on the ability of tyrosine kinase inhibitors (TKIs) to inhibit EGFR, they 
can be divided in two types, those targeting the active state, such as Iressa, and those 
targeting the inactive state, such as erlotinib and lapatinib [17–20]. Lapatinib showed 
dual activity on EGFR/HER2 [21–26]. Despite the benefits of using these TKIs, 
the employment of them has been linked to severe side effects and drug resistance 
[27–30]. Therefore, it is necessary to identify new compounds, either through drug 
design or drug repurposing, that target EGFR and/or HER2 receptors and are effective 
for cancer therapy. In this context, the combination of docking and molecular dynam-
ics (MD) simulations has been widely exploited to generate new information about the 
binding properties between natural or synthetic TKIs and EGFR/HER2 [10, 11, 19, 20, 
31–35]. In a previous study, Hui et al. explored the inhibitory properties of doxazosin, 
an α-1 antagonist used for the treatment of hypertension, in two human breast cancer 
cell lines: BCC MDA-MB-231 and MCF-7 cells [36]. MDA-MB-231 and MCF-7 cells are 
estrogen receptor (ER) positive and ER negative, respectively [37], and both cell lines 
also expressed EGFR and HER2; however, MDA-MB-231 expressed both receptors 
in higher concentrations than MCF-7 [38]. Although EGFR and HER2 are important 
regulators for normal cellular processes, their dysregulation has been associated to 
protein overexpression that leads to the development of different types of cancer [1, 
5]. They demonstrated that doxazosin induces apoptosis in breast cancer cell lines 
similar to Iressa (Gefitinib), reducing phosphorylated EGFR by a mechanism that does 
not involve the α1-adrenergic receptor, however, the structural and energetic basis 
for its inhibitory properties is poorly understood. In addition, Sharkawi et al. identi-
fied similar experimental antiproliferative activity of doxazosin in an MCF-7 cell line 
through the inhibition of EGFR [39]. Thus, more robust structural and energetic stud-
ies are required to provide structural insight into the affinity of doxazosin for EGFR/
HER2 compared with gefitinib. Structural data, docking, and molecular dynamics 
(MD) simulations combined with the MMGBSA approach were used to elucidate the 
molecular mechanism through which doxazosin and gefitinib inhibit EGFR/HER2.
2. Methods
2.1 Structural modeling
The free forms of EGFR in the inactive (EGFRIN) and active (EGFRAC) states were 
taken from the crystallographic structures of EGFRIN (PDB entry 1XKK) and EGFRAC 
(PDB entry 1 M17) conformations. The free forms of HER2 in the inactive (HER2IN) 
and active (HER2AC) states were taken from previous MD simulation studies; HER2IN 
[10] and HER2AC [11] conformations. Amino acid residues missing in the electron 
density map of EGFR structures were built with MODELER Version 9.14 [40].
2.2 Docking studies
Docking calculations were carried out using AutoDock 4.2 and AutoDock 
Tools 1.5.6 software [41]. The ligand structures were built and optimized with 
the Gaussian package [42]. The initial geometries of ligands were optimized 
at the AM1 level. Hydrogen atoms were added to ligands and receptors, and 
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Kollman and Gasteiger partial charges were assigned for ligand and proteins, 
respectively. The affinity grid maps were constructed on the receptor using a 
grid size of 70 × 70 × 70 Å and 0.370 Å of spacing. Due to the stochastic nature of 
the Lamarckian algorithm, 20 runs were performed for each compound, and 30 
conformations of the ligand (binding poses) were observed between ligand and 
protein. The best binding poses were selected using the criteria of having the lowest 
energetic conformations at the receptor binding site.
2.3 Molecular dynamics simulations
The protein-ligand results obtained by docking were checked through MD 
simulation studies. MD simulations were carried out using the AMBER16 package 
[43], in conjunction with the ff14SB force field [44]. The systems simulated were 
put into a space-filling dodecahedric box of 12 Å, solvated with TIP3P water model 
[45], and neutralized with sodium and chloride ions (0.10 M) to create a physiologi-
cal concentration. The parameterizations of the ligands were performed assigning 
AM1-BCC atomic charges and matching the atoms with the general Amber force 
field (GAFF) [46]. Once the systems were constructed, they were minimized using 
steepest descent with position restraint of the ligands, followed by steepest descent 
without position restraint and conjugate gradients. The minimized systems were 
then submitted to 100 ns-long MD simulations using an NPT ensemble with the 
velocity rescaling arrangement to simulate a constant temperature at 310 K. A con-
stant temperature and pressure (1 atm) were maintained using the weak-coupling 
algorithm [47], with coupling constants τT and τP of 1.0 and 0.2 ps, respectively. 
The electrostatic term was described by the PME method [48], and a 10 Å cut-off 
was selected for the van der Waals interactions. The time step for the MD simula-
tions was set to 2.0 fs. The SHAKE algorithm [49] was employed to reset bonds to 
their right lengths after an unconstrained update. The conformations obtained from 
MD simulations at intervals of 20 picoseconds (ps) were analyzed using the cpptraj 
tool in Amber16. Plots of variation of root mean squared deviation (RMSD) and 
radius of gyration (RG) were generated to evaluate convergence. Clustering analysis 
using a cutoff of 2.5 Å was performed to identify the most populated conformation 
in the simulation. Principal components (PC) analysis along the most essential 
eigenvectors was carried out to evaluate total flexibility. A map of interactions was 
generated using Maestro Version 10.1, 2015–1 [50].
2.4 Affinity prediction and per-residue decomposition
The binding free energy (ΔGbind) and per residue contribution were determined 
using the MMGBSA method [51–54]. Analysis was carried out using a total of 500 
protein-ligand conformers at intervals of 100 ps (over the last 50 ns of simulation), 
considering a salt concentration of 0.10 M and implicit solvent models [55]. The bind-
ing free energy (ΔGbind) and per-residue decomposition for each complex was calcu-
lated as previously described [11] and were the average result of triplicate experiments.
3. Results and discussion
3.1 Convergence and equilibrium
The stability of the evaluated systems was observed by measuring two geo-
metrical parameters. The root mean squared deviation (RMSD) and the radius of 
gyration (RG) were determined to identify the time at which the systems reached 
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convergence (Table 1). RMSD analysis showed that free and bound EGFR/HER2 
systems reached stability between 20 to 50 ns with RMSD values, which oscil-
lated between 1.40 and 4.20 Å. RG examination revealed that free and bound 
EGFR/HER2 systems exhibited stability from 20 to 50 ns with values oscillating 
between 18.8 and 20.2 Å. Based on this result, further analysis was carried out 
discarding the first 50 ns.
Figure 1. 
Map of interactions for the most populated conformation of EGFR/HER2–doxazosin systems. Binding 
conformations and map of interaction for EGFRAC-doxazosin (A) EGFRIN-doxazosin (B) HER2AC-doxazosin (C) and 















Average geometrical values (Å) over the last 50 ns of 100-ns-long MD simulations.
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3.2 Structural analysis of complexes between doxazosin and EGFRAC/EGFRIN
To explore the structural differences between doxazosin and gefitinib on  
EGFR/HER2, the most populated receptor-ligand conformations were retrieved 
over the equilibrated simulation time (the last 50 ns) through clustering analysis. 
Analysis of the complex between doxazosin and EGFRAC showed that the ligand 
was stabilized through van der Waals interactions with Phe723, Val726, Leu792, 
Met793, Pro794, Phe795, Cys797, Leu799, and Leu844, and polar interactions with 
Gly719, Lys745, Gly796, Asp800, Asp837, Arg841, Asn842, and Asp855 (Figure 1A). 
In contrast, Val718 formed both van der Waals interactions and a hydrogen bond 
with the quinazoline ring of doxazosin. In the complex with EGFRIN, dozaxosin 
was bound through van der Waals interactions with Phe723, Val718, Val726, Ala743, 
Leu792, Phe795, Tyr801, and Leu844. The polar contact took place with Lys745, 
Gln791, Gly796, Glu804, and His805. Met793 formed both van der Waals interac-
tions and one hydrogen bond with the benzodioxin moiety of doxazosin. Pro794 
established both van der Waals contacts and one hydrogen bond with the quinazo-
line ring of doxazosin, whereas Glu804 formed hydrogen bonds with the quin-
azoline ring of doxazosin (Figure 1B). Stabilization of doxazosin did not establish 
interactions with Thr790 and Met766, two residues whose mutations have been 
linked to EGFR drug resistance [56, 57]. In addition, the characteristic interactions 
between Met793 and the quinazoline moiety were not observed, which has previ-
ously been observed for other TKIs of EGFR [10].
3.3 Structural analysis of complexes between doxazosin and HER2AC/HER2IN
Dozaxosin in complex with HER2AC was bound through van der Waals interac-
tions with Leu726, Val734, Ala751, Phe864, Leu852, and Leu800 and polar interac-
tions with Gly727, Ser783, Thr798, Gln799, Arg849, Thr862, Asp863, and Lys921 
(Figure 1C). For the complex between doxazosin and HER2IN, the ligand was 
stabilized by Val754, Leu755, Met774, Leu785, Leu796, Pro802, Cys805, Leu852, 
and Phe864 and polar contacts with Lys753, Arg756, Gln799, Thr862, and Asp863. 
Tyr803 and Met801 formed van der Waals and hydrogen bonds with polar groups 
of the quinazoline ring, whereas Ser783 and Thr798 formed polar contacts with 
the linker between piperazine and the benzodioxin moiety (Figure 1D). Structural 
comparison of the complexes of doxazosin with HER2AC/HER2IN showed that 
doxazosin was better coordinated on HER2IN than HER2AC through more well-
adjusted types of van der Waals and hydrogen bonds. In addition, the characteristic 
hinge hydrogen bond between Met801 and the polar atoms of the quinazoline 
moiety of several TKIs [31, 58] was present only in for the complex with doxazosin 
and HER2IN.
3.4 Structural analysis of complexes between gefitinib and EGFRAC/EGFRIN
Analysis of complexes between gefitinib and EGFRAC illustrated that the 
ligand was bound through van der Waals interactions with Leu718, Val726, Ala743, 
Met766, Leu788, Ile789, Leu792, Pro794, Phe795, Cys797, Leu844, and Phe856. 
The polar interactions were through contacts with Gly719, Ser720, Gly721, Lys745, 
Glu762, Thr790, Gln791, Gly796, Arg803, Thr854, and Asp855. Met793 formed 
van der Waals interactions and one polar interaction with the quinazoline ring of 
gefitinib, whereas Asp800 formed a hydrogen bond with one of the substituents at 
the quinazoline ring (Figure 2A). In complex with EGFRIN, gefitinib was stabilized 
by van der Waals contacts with Phe723, Val718, Val726, Ala743, Cys775, Leu792, and 
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Cys797. The polar contacts were through Gly719, Ser720, Gly721, Gly724, Thr790, 
Gln791, Arg841, Asn842, Thr854, and Asp 855. Met793 established both van der 
Waals interactions and one hydrogen bond with the quinazoline ring, whereas 
Lys745 made a hydrogen bond with one of the substituents of the quinazoline ring 
(Figure 2B). Comparison of the map of interactions of both complexes showed 
that gefitinib was better coordinated on EGFRIN than EGFRAC. In both complexes, 
gefitinib established interactions with Thr790, a residue whose mutation is linked 
to EGFR drug resistance [56, 57]. In addition, in both complexes, the characteristic 
interactions between Met793 and the quinazoline moiety of ligand were observed, 
which has been reported elsewhere [10].
3.5 Structural analysis of complexes between gefitinib and HER2AC/HER2IN
Gefitinib in complex with HER2AC was bound through van der Waals  
interactions by Leu726, Val734, Leu800, Cys805, Leu807, Val851, and Leu852 
(Figure 2C). Polar interactions were stabilized by Gly727, Ser728, Gly729, Asp808, 
Asp845, Arg849, Asn850, Thr862, and Gly865 residues, whereas Asp863 formed a 
hydrogen bond with one of the substituents of the quinazoline ring (Figure 2C). 
Gefitinib formed a complex with HER2IN, coordinated by Leu726, Val734, Val731, 
Cys805, Leu807, Leu866, Ala867, Leu869, Tyr923, Ala920, and Pro922 residues 
through van der Waals interactions. Polar interactions took place by Gly727, Ser728, 
Lys753, Arg811, Arg849, Asp863, and Lys921 residues, whereas Asp808 formed 
a hydrogen bond with one of the quinazoline ring substituents (Figure 2D). 
Structural comparison of both systems depicted that gefitinib was better stabilized 
on HER2IN than HER2AC. In addition, in both complexes, the characteristic polar 
interaction between Met801 and polar atoms of the quinazoline moiety of ligand 
was not observed [31, 58], as observed for the complex between doxasozin and 
HER2IN (Figure 1C).
Figure 2. 
Map of interactions for the most populated conformation of EGFR/HER2–gefitinib systems. Binding 
conformations and map of interaction for EGFRAC-gefitinib (A) EGFRIN-gefitinib (B) HER2AC-gefitinib (C) and 
HER2IN-gefitinib (D). The map of interactions was performed with maestro Schrödinger version 10.1.
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3.6 Binding free energy
Determination of the ΔGbind values was performed using the MMGBSA method. 
Table 2 shows that all systems exhibited thermodynamically favorable ΔGbind 
values. Nonpolar contributions formed by van der Waals energy (ΔEvdw) and 
nonpolar desolvation (ΔGnpol,sol) guided the binding of the complexes. Comparative 
analyses of the complexes between doxazosin or gefitinib on HER2AC, HER2IN, 
EGFRAC, and EGFRIN showed that doxazosin reached more favorable ΔGbind values 
on HER2IN than on EGFRAC, EGFRIN, and HER2AC. Gefitinib showed a higher affin-
ity for EGFRIN than EGFRAC, HER2AC, and HERIN. Comparative analysis between 
the affinity of doxazosin and gefitinib for the four systems showed that doxazosin 
reached more favorable affinity for HER2IN than gefitinib, whereas gefitinib 
reached higher affinity for EGFRAC than doxazosin. The results suggested that the 
inhibitory activity of doxazosin in breast cancer cell lines is by mainly targeting 
HER2IN, whereas that for gefitinib is mainly through inhibiting EGFRAC, in line with 
previous studies where the selectivity of gefitinib toward EGFRAC was observed 
[59]. In addition, this analysis showed that the binding properties of doxazosin 
could be improved by exploring how changes in the binding affinity of new deriva-
tives of doxazosin coupled on HER2IN.
3.7 Decomposition of the per-residue free energy
This analysis identified the residues that contributed the most to the ΔGbind 
value for each complex. Table 3 shows that Leu718, Gly719, Phe723, Val726, Cys797, 
Leu799, Arg841, and Leu844 were the major contributors in the stabilization of 
the EGFRAC-doxazosin complex, from which Leu718 established hydrogen bonds with 
polar atoms of the quinazoline ring of doxazosin (Figure 1A). In the EGFRIN-doxazosin 
complex, Leu718, Val726, Ala743, Leu792, Met793, Pro794, Phe795, Gly796, Tyr801, 
Glu804, and Leu844 were the main stabilizers of this system. From these residues, 
Met793, Pro794, and Glu804 formed hydrogen bonds, stabilizing the quinazoline 
and benzodioxine rings of doxazosin (Figure 1B). In the EGFRAC-gefitinib complex, 
Leu718, Val726, Ala743, Lys745, Met766, Ile789, Thr790, Gln791, Leu792, Met793, 
Gly796, Cys797, and Thr854 were key residues in the affinity of gefitinib. Among 
these residues, the participation of Met793 through a hydrogen bond was appreci-
ated (Figure 2A), whereas Leu718, Gly719, Val726, Ala743, Lys745, Leu792, Met793, 
Cys797, Asn842, Leu844, and Thr854 were the major contributors to the ΔGbind 
value in the EGFRIN-gefitinib complex. Of these residues, the participation of Lys745 
Systems ΔEvdw ΔEele ΔGele,sol ΔGnpol,sol ΔGbind
EGFRAC-doxazosin −43.52 (5.13) 22.33 (4.91) −2.69 (0.80) −5.46 (0.50) −29.33 (6.14)
EGFRIN-doxazosin −38.78 (3.90) 3.25 (0.91) 9.68 (2.80) −4.62 (0.37) −30.46 (4.20)
HER2AC-doxazosin −36.77 (6.0) 40.15 (12.0) −21.06 (11.0) −4.36 (0.55) −22.05 (4.60)
HER2IN-doxazosin −48.93 (4.0) 23.99 (9.0) −7.39 (1.50) −5.99 (0.30) −38.32 (4.0)
EGFRAC-gefitinib −55.01 (0.16) −11.11 (0.65) −25.40 (0.60) −7.16 (0.01) −47.88 (0.17)
EGFRIN-gefitinib −44.10 (0.15) 27.00 (0.69) −16.48 (0.65) −5.74 (0.01) −39.32 (0.23)
HER2AC-gefitinib −34.76 (4.0) 38.46 (16.0) −22.98 (5.0) −4.90 (0.70) −24.18 (5.0)
HER2IN-gefitinib −38.78 (5.7) −31.92 (13.0) 49.70 (1.50) −4.90 (0.50) −25.91 (6.0)
Table 2. 
Binding free energy components of protein-ligand systems (in units of kcal/Mol).
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and Met793 were important in the stabilization of quinazoline and substitution at 
the quinazoline ring (Figure 2B).
Table 4 shows that Leu726, Gly727, Ser728, Val734, Asp863, and Phe864 
contributed the most to the ΔGbind value of the HER2AC-doxazosin complex. Met774, 
Ser783, Leu785, Leu796, Thr798, Met801, Tyr803, Gly804, Cys805, Leu852, Thr862, 
and Phe864 were the major residues stabilizing the HER2IN-doxazosin complex. The 
participation of Ser783, Thr798, Met801, and Tyr803 was visualized through the 
formation of hydrogen bonds with gefitinib (Figure 1D). Leu726, Cys805, Leu807, 
Arg849, Asn850, Leu852, and Thr862 were the main contributors in the HER2AC-
gefitinib complex (Table 4). Leu726, Phe731, Val734, Cys805, Leu807, Arg849, 
Leu866, Pro922, and Tyr923 contributed the most to the ΔGbind value in the  
HER2IN-gefitinib complex.
3.8 Principal component analysis
We evaluated the differences in mobility for the free and bound EGFR/HER2 
systems via PC analysis. Evaluation of the quantification of the diagonalized covariance 
matrix based on covariance showed the following values: HER2AC, 15.0 nm
2;  
Residue EGFRAC-doxazosin EGFRIN-doxazosin EGFRAC-gefitinib EGFRIN-gefitinib
Leu718 −1.071 −2.243 −1.664 −1.261
Gly719 −0.532 −0.871
Phe723 −2.805
Val726 −1.325 −0.674 −2.183 −1.705






Leu792 −1.257 −1.663 −1.897










Leu844 −0.935 −0.809 −2.063
Thr854 −0.839 −1.069
Table 3. 
Per-residue free energy for complexes between doxazosin and gefitinib with EGFRAC/EGFRIN (values  
kcal/Mol).
9















2. This result indicates that the molecular recognition of 
doxazosin or gefitinib on HER2AC, HER2IN, and EGFRAC decreased the number of 
conformational states compared to that of free HER2AC, HER2IN, and EGFRAC states. 
However, this conformational reduction was more significant for the free and bound 
HER2IN system. In contrast, a small increase in the conformational mobility was 
experienced upon the coupling of gefitinib by EGFRIN. This indicated that doxazosin 
and gefitinib binding to HER2IN was linked with reduced heterogeneity, which suggests 
that this molecular recognition was associated with an unfavorable entropy contribu-
tion that could contribute to decrease the favorable ΔGbind values for HER2IN-doxazosin 
and HER2IN-gefitinib, as seen in Table 2.
4. Conclusion
In this chapter, we explored the structural and energetic features that guide 
the similar inhibitory properties of doxazosin with gefitinib in overexpressing 
Residue HER2AC-doxazosin HER2IN-doxazosin HER2AC-gefitinib HER2IN-gefitinib
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EGFR/HER2 cell lines combining docking and MD simulation with the MMGBSA 
approach. Based on these studies, we identified that doxazosin was able to target 
the active and inactive states of EGFR and HER2, however, its inhibitory activity 
against breast cancer cell lines was mainly by targeting HER2IN. Similarly, although 
gefitinib was able to target the inactive and inactive states of EGFR and HER2, its 
activity mainly targeted EGFRAC, in line with previous reports. Per-residue free 
energy analysis identified the key residues stabilizing HER2IN-DOX and EGFRAC-GEF 
systems, showing that in the stabilization of both systems, Met793 and Met801 were 
involved for EGFR and HER2, respectively. These residues stabilized HER2IN-DOX 
and EGFRAC-GEF systems through the formation of hydrogen bonds with the quinaz-
oline ring, as reported for other TKIs. This study provides structural and energetic 
information that can be used to design new inhibitors for HER2IN or EGFRAC using 
doxazosin or gefitinib, respectively, as a pharmacophoric model.
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